ClinicalTrials.gg

Program

Interleukin-2

Also written as “Recombinant Human Interleukin-2 and Rituximab”, “IL-2 (interleukin 2)” and “Interleukin 2 subcutaneous injection”.

Its studies are mostly in Lymphoma, Non-Hodgkin · Carcinoma, Renal Cell · Carcinoma, Non-Small-Cell Lung · Melanoma · Neoplasms, led by 3 companies.

Furthest: phase 4, since Sep 12, 20026 company-led studies, 2 open or runningNext primary completion: Aug 30, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Chiron30 open or runningphase 3since Sep 12, 2002Sep 12, 2002none ahead
Hangzhou Huasai Biomedicine22 open or runningphase 1since Jul 22, 2025Jul 22, 2025Aug 30, 2027phase 1 · NCT07105176
Clinigen10 open or runningphase 4since May 10, 2013May 10, 2013none ahead

Also a collaborator on its studies: orion-clinical-services.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 12, 2002First study: phase 3 study in Lymphoma, Non-HodgkinNew to ChironChiron · NCT00045877 · United States
  2. Sep 12, 2002Phase 2 study in Lymphoma, Non-HodgkinChiron · NCT00045864 · United States
  3. Jan 6, 2005Phase 2 study in Lymphoma, Non-HodgkinChiron · NCT00100737 · 300 enrolled · United States
  4. May 10, 2013Clinigen's first study: phase 4 study in MelanomaNew to ClinigenClinigen · NCT01856023 · 29 enrolled · United States
  5. Jul 22, 2025Hangzhou Huasai Biomedicine's first study: phase 1 study in Advanced Non-Small Cell Lung CancerNew to Hangzhou Huasai BiomedicineHangzhou Huasai Biomedicine · NCT07105176 · 12 planned · China
  6. Sep 15, 2026Phase 1 study in Advanced NSCLCHangzhou Huasai Biomedicine · NCT07830342 · 24 planned · China

Ahead

  1. Aug 30, 2027Primary completion: phase 1 study in Advanced Non-Small Cell Lung CancerHangzhou Huasai Biomedicine · NCT07105176
  2. Oct 2028Primary completion: phase 1 study in Advanced NSCLCHangzhou Huasai Biomedicine · NCT07830342

TargetBeta

“Interleukin-2 receptor agonist”ChEMBL 37, by rule

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07830342Advanced NSCLC · China1RecruitingHangzhou Huasai BiomedicineOct 202824
NCT07105176Advanced Non-Small Cell Lung Cancer · China1RecruitingHangzhou Huasai BiomedicineAug 30, 202712
NCT01856023Melanoma · United States4TerminatedClinigenJul 201529
NCT00100737Lymphoma, Non-Hodgkin · United States2TerminatedChiron300
NCT00045877Lymphoma, Non-Hodgkin · United States3CompletedChiron
NCT00045864Lymphoma, Non-Hodgkin · United States2CompletedChiron

How it is read

Names in the registry

  • “Interleukin-2”, 3 entries
  • “Recombinant Human Interleukin-2 and Rituximab”, 2 entries
  • “IL-2 (interleukin 2)”, 1 entry
  • “Interleukin 2 subcutaneous injection”, 1 entry
  • “High Dose Interleukin-2”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.